Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03859830
Other study ID # BXU012184
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 22, 2019
Est. completion date November 9, 2019

Study information

Verified date December 2019
Source Baxter Healthcare Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The incidence and prevalence of chronic kidney disease are increasing worldwide, as is the number of patients progressing to End-Stage Renal Disease (ESRD). China has experienced an increased accessibility and affordability of dialysis treatment, which in turn has brought about an increase in the number of patients receiving Renal Replacement Therapy (RRT).Without RRT, either in the form of maintenance dialysis or transplantation, ESRD is fatal.

The scope of the trial is to observe the performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line versus AK 200 Ultra S, extracorporeal circulation conduct of blood purification apparatus and Ultra Steriset as the comparator devices in treatment of patients using hemodialysis (HD) or hemodiafiltration (HDF) for ESRD.


Recruitment information / eligibility

Status Completed
Enrollment 276
Est. completion date November 9, 2019
Est. primary completion date November 9, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients =18 to =75 years of age with diagnosis of ESRD

- Patients on thrice weekly HD for a minimum of 3 months who received at least one 4 hour HDF treatment in the past two weeks prior to study enrollment with a total convection volume (VCtot) (including UF) of equal or greater than 16 L post-dilution

- Body weight (BW) = 40 Kg

- Patients with stable dialysis profiles:

1. Kt/Vurea = 1.2 which is taken within 4 weeks before study enrollment

2. Dialysis prescription stable over 6 recent treatments

- Patients on stable anticoagulation dose

- Patients who have an adequate arteriovenous fistula (AVF) or graft, capable of providing a QB with 200-300 mL/min range

- Patients able to give informed consent (IC) after an explanation of the proposed study

- Patients who receive in-center treatment HD at a site that routinely implements high flux dialysis and/or HDF

Exclusion Criteria:

- Patients who are human immunodeficiency virus (HIV) positive, or with active Hepatitis A (HAV), Hepatitis B (HBV) or Hepatitis C (HBC)

- Patients with known hemodynamic instability, bleeding risks and coagulation disorders

- Patients with active or ongoing infection

- Patients with advanced liver, heart or pulmonary disease, as judged by the Investigator, that would not be suitable for participation in the study

- Patients with any comorbidity possibly conflicting with the study purpose or procedures as judged by the Investigator

- Patients who are currently participating in other interventional clinical trials or have participated in another interventional clinical trial within one (1) month of the current study that may interfere with this study as judged by the Investigator.

- Pregnant women, lactating women and women or men who plan to have a baby and refuse to apply the effective contraceptive methods during the study period

- Patients with active cancer

- Patients who have acute renal failure

- Patients who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to PD within the next two months, or who require single needle dialysis therapy

- Patients diagnosed with New York Heart Association (NYHA) Class IV congestive heart failure, or acute coronary syndrome and/or who have suffered a myocardial infarction within the three months prior to the start of the study

- Patients with a history of severe mental disorders

- Patients who have had an allergic response to polyarylethersulfone or polysulfone membrane

Study Design


Intervention

Device:
Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line
The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
AK200 Ultra S, extracorporeal circulation conduct of blood purification
The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

Locations

Country Name City State
China Baxter Investigational Site Beijing Beijing
China Baxter Investigational Site Foshan Guangdong
China Baxter Investigational Site Hangzhou Zhejiang
China Baxter Investigational Site Nanjing Jiangsu
China Baxter Investigational Site Shenyang Liaoning
China Baxter Investigational Site Wenzhou Zhejiang
China Baxter Investigational Site Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Baxter Healthcare Corporation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants successfully completing HDF without interruption of therapy during Dialysis Defined as participants not having an interruption in therapy for greater than 15 continuous minutes due to a technical reason of all the enrolled patients in the same group. If there is more than one interruption due to technical reasons, the criteria for failure should be the sum of all interruptions being greater than 15 minutes. Day 1 (One Midweek HDF Treament Session, 4 hour duration)
Primary Number of Participants by Level of Effectiveness of Disposable Tubing during and after Dialysis Participant recorded as "yes" or "no" by categories of (1) blood flow in the tubing is smooth without obstruction, blood flow rate meets requirement of the patient's hemodialysis prescription and finish the dialysis procedure, the (2) connections are free from blood and air leakage and detachment, (3) there is no folding, cracking or rupture in tubing during dialysis procedure. Day 1 (One Midweek HDF Treament Session, 4 hour duration)
Primary Reduction ratio of ß2-Microglobulin during and after Dialysis Day 1 (One Midweek HDF Treament Session, 4 hour duration)
Secondary Single-pool Kt/V urea during and after Dialysis Computing formula: spKt/V = -ln (R - 0.008t) + (4 - 3.5R) x (?BW/BW). Where R is the blood urea after hemodialysis/ blood urea before hemodialysis; t is time in hours; ?BW is the weight change values after hemodialysis, namely ultrafiltration volume in liters; BW is weight in kilograms. Day 1 (One Midweek HDF Treament Session, 4 hour duration)
Secondary Urea Reduction Ratio (URR) during and after Dialysis Day 1 (One Midweek HDF Treament Session, 4 hour duration)
Secondary Number of Participants by Level of Appearance of Disposable Tubing during and after Dialysis Participants with tubing as flexible, transparent, and smooth (it is easy to observe the presence of bubbles) recorded categorically as "yes" or "no." Day 1 (One Midweek HDF Treament Session, 4 hour duration)
Secondary Number of Participants by Level of Elasticity of Pump Lines during and after Dialysis Participants with the blood and fluid lines showing good elasticity and good resilience after being rolled without obvious deformity after dialysis recorded categorically as "yes" or "no." Day 1 (One Midweek HDF Treament Session, 4 hour duration)
See also
  Status Clinical Trial Phase
Completed NCT04087213 - Study of HemoCareā„¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD N/A
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease N/A
Withdrawn NCT01691196 - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed NCT01394341 - Liraglutide Treatment to Patients With Severe Renal Insufficiency Phase 4
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4
Completed NCT00307463 - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Phase 4
Recruiting NCT00155363 - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Phase 4
Completed NCT00234156 - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers N/A
Completed NCT00586131 - Arterial pH and Total Body Nitrogen Balances in APD Phase 4
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Recruiting NCT04575077 - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Recruiting NCT03862859 - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis Phase 4
Terminated NCT03661229 - Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device N/A
Completed NCT03288922 - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF N/A
Completed NCT02360748 - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients N/A
Completed NCT02572882 - Gut Microbiome and p-Inulin in Hemodialysis N/A